X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (235) 235
index medicus (229) 229
irreversible inhibitors (189) 189
growth-factor receptor (137) 137
chemistry, medicinal (130) 130
receptor, epidermal growth factor - antagonists & inhibitors (108) 108
egfr (107) 107
tyrosine kinase inhibitors (106) 106
oncology (105) 105
acquired-resistance (103) 103
animals (97) 97
protein kinase inhibitors - pharmacology (93) 93
cell lung-cancer (88) 88
gefitinib (87) 87
cancer (83) 83
cell line, tumor (77) 77
irreversible inhibitor (75) 75
mutation (73) 73
tyrosine kinase (73) 73
antineoplastic agents - pharmacology (72) 72
pharmacology & pharmacy (72) 72
biochemistry & molecular biology (70) 70
protein kinase inhibitors - chemistry (67) 67
receptor, epidermal growth factor - metabolism (66) 66
structure-activity relationship (66) 66
lung neoplasms - drug therapy (64) 64
tyrosine kinase inhibitor (57) 57
carcinoma, non-small-cell lung - drug therapy (55) 55
chemistry, organic (55) 55
tyrosine (55) 55
drug design (53) 53
epidermal growth factor (52) 52
antineoplastic agents - chemistry (49) 49
lung cancer (48) 48
molecular structure (48) 48
quinazolines - pharmacology (48) 48
receptor, epidermal growth factor - genetics (47) 47
epidermal growth factor receptor (46) 46
protein kinase inhibitors - therapeutic use (46) 46
analysis (44) 44
antineoplastic agents - therapeutic use (44) 44
lung cancer, non-small cell (44) 44
mice (44) 44
resistance (43) 43
erlotinib (42) 42
cell proliferation - drug effects (41) 41
female (41) 41
models, molecular (40) 40
mutations (39) 39
drug discovery (36) 36
lung neoplasms - genetics (36) 36
quinazolines - chemistry (36) 36
tumors (35) 35
afatinib (34) 34
phase-ii trial (33) 33
antineoplastic agents - chemical synthesis (32) 32
antitumor-activity (32) 32
discovery (32) 32
kinases (32) 32
neoplasms - drug therapy (32) 32
potent (32) 32
design (31) 31
open-label (31) 31
biological evaluation (30) 30
carcinoma, non-small-cell lung - genetics (30) 30
drug resistance, neoplasm (30) 30
protein kinase inhibitors - chemical synthesis (30) 30
inhibitors (29) 29
lung-cancer (29) 29
t790m mutation (29) 29
chemotherapy (28) 28
enzyme inhibitors (28) 28
chemistry, multidisciplinary (27) 27
1st-line treatment (26) 26
care and treatment (26) 26
dose-response relationship, drug (26) 26
growth-factor-receptor (26) 26
receptor, erbb-2 - antagonists & inhibitors (26) 26
cysteine (25) 25
quinazolines - therapeutic use (25) 25
drug resistance (24) 24
drug-resistance (24) 24
phosphorylation (24) 24
protein binding (24) 24
research (24) 24
drug screening assays, antitumor (23) 23
enzyme inhibitors - pharmacology (23) 23
health aspects (23) 23
irreversible egfr (23) 23
lung neoplasms - pathology (23) 23
male (23) 23
breast cancer (22) 22
egf receptor (22) 22
non-small cell lung cancer (22) 22
nsclc (22) 22
quinazolines - chemical synthesis (22) 22
respiratory tract diseases (22) 22
activation (21) 21
breast-cancer (21) 21
drug resistance, neoplasm - genetics (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | MUTATIONS | AFATINIB | IRREVERSIBLE EGFR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 05/2017, Volume 25, Issue 10, pp. 2713 - 2723
Journal Article
Cancer Letters, ISSN 0304-3835, 2013, Volume 340, Issue 1, pp. 88 - 96
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 05/2018, Volume 26, Issue 8, pp. 1740 - 1750
A series of novel quinazoline derivatives bearing various C-6 benzamide substituents were synthesized and evaluated as EGFR inhibitors, and most showed... 
High selectivity | Quinazoline | Anti-cancer | Kinase inhibitor | EGFR | IRREVERSIBLE INHIBITORS | GEFITINIB | DESIGN | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACQUIRED-RESISTANCE | CHEMISTRY, ORGANIC | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | 1ST GLOBAL APPROVAL | SKIN | ERLOTINIB | Liver
Journal Article
Journal Article
Journal of Receptors and Signal Transduction, ISSN 1079-9893, 11/2018, Volume 38, Issue 5-6, pp. 393 - 412
Journal Article